OBJECTIVES: This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment. METHODS: Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed. RESULTS: Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤ 6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely. CONCLUSIONS: These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.
OBJECTIVES: This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment. METHODS: Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed. RESULTS: Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤ 6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely. CONCLUSIONS: These results demonstrate that relapsed multiple myelomapatients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.
Authors: Philippe Moreau; Paul G Richardson; Michele Cavo; Robert Z Orlowski; Jesús F San Miguel; Antonio Palumbo; Jean-Luc Harousseau Journal: Blood Date: 2012-05-29 Impact factor: 22.113
Authors: J Laubach; L Garderet; A Mahindra; G Gahrton; J Caers; O Sezer; P Voorhees; X Leleu; H E Johnsen; M Streetly; A Jurczyszyn; H Ludwig; U-H Mellqvist; W-J Chng; L Pilarski; H Einsele; J Hou; I Turesson; E Zamagni; C S Chim; A Mazumder; J Westin; J Lu; T Reiman; S Kristinsson; D Joshua; M Roussel; P O'Gorman; E Terpos; P McCarthy; M Dimopoulos; P Moreau; R Z Orlowski; J S Miguel; K C Anderson; A Palumbo; S Kumar; V Rajkumar; B Durie; P G Richardson Journal: Leukemia Date: 2015-12-29 Impact factor: 11.528
Authors: Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson Journal: Blood Date: 2014-01-15 Impact factor: 22.113